AINewsnow

Why An AI Biotech Startup Launched A $600 Million Fund To Buy Stalled Drugs

Most AI drug development firms are focused on discovery. AI biotech Formation Bio is betting the real bottleneck is clinical trials. With a new $600 million fund to buy or license potential drugs that have stalled out, the startup now hopes to prove that it’s right.

Read the full story at Forbes AI ↗

Timeline · 1 report

  1. 2026-10-28 13:00 · Forbes AI
    Why An AI Biotech Startup Launched A $600 Million Fund To Buy Stalled Drugs

More stories

  1. Anthropic reveals plans for blockbuster IPO — Sky News Technology
  2. Meta's Waddle World is a Tamagotchi-like AI pet app — Engadget
  3. Anthropic's IPO filing shows soaring sales and steep losses — France 24 — Artificial Intelligence
  4. DeepMind unveils Genie 4 world model promising more realistic physics and humans — Ars Technica AI
  5. ChatGPT’s Advice to Cut Her Seizure Drug Led to Devastating Consequences — New York Times AI
  6. Artificial Analysis launches the Intelligence Index v5, with new coding and science benchmarks, built on private datasets; Claude Opus 5.5 (max) leads at 58 (@artificialanlys) — Techmeme
  7. Why Merge CEO Shensi Ding stays hands-on with Codex — OpenAI YouTube
  8. People are using AI to make expensive computer programs free. This could change everything — The Conversation AI (US)

Get the daily brief of stories like this at 6:30 every morning →